Literature DB >> 9449285

Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast.

J Z Montgomerie1, D G Schick.   

Abstract

The in vitro bactericidal interaction of trovafloxacin and rifampin against Enterococcus spp. has indicated that antagonism occurs between these two antimicrobial agents. This drug combination was examined in vivo in rats with experimental pyelonephritis. The rats received trovafloxacin, rifampin, or both drugs. On the basis of the mean log10 CFU of Enterococcus faecalis from the kidneys, there was no evidence that trovafloxacin and rifampin were antagonistic in vivo.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9449285      PMCID： PMC105480     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.

Authors:  N K Henry; M S Rouse; A L Whitesell; M E McConnell; W R Wilson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

2.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

3.  Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents.

Authors:  G A Losonsky; A Wolf; R S Schwalbe; J Nataro; C B Gibson; E W Lewis
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

4.  Pyelonephritis. XII. Comparison of penicillin, ampicillin, and streptomycin in enterococcal infection in rats.

Authors:  F L Sapico; G M Kalmanson; J Z Montgomerie; W L Hewitt; L B Guze
Journal:  J Infect Dis       Date:  1971-06       Impact factor: 5.226

5.  In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.

Authors:  D G Schick; H N Canawati; J Z Montgomerie
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

6.  Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.

Authors:  L L Livornese; S Dias; C Samel; B Romanowski; S Taylor; P May; P Pitsakis; G Woods; D Kaye; M E Levison
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

7.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.

Authors:  R Teng; D Girard; T D Gootz; G Foulds; T E Liston
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pyelonephritis. I. Observations on the course of chronic non-obstructed enterococcal infection in the kidnev of the rat.

Authors:  L B GUZE; B H GOLDNER; G M KALMANSON
Journal:  Yale J Biol Med       Date:  1961-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.